200
Participants
Start Date
August 31, 2015
Primary Completion Date
September 15, 2020
Study Completion Date
September 15, 2020
Dabigatran
"* Antral pulmonary vein ablation for patients with AF~* left atrial fibrosis/electrical scar assessment by electroanatomical mapping~* followed by 6 months OAC (3 months blanking period + 3 months observation period)~* in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~* followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~* Experimental arm (group A): OAC with dabigatran for 12 months~* Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
Hannover Medical School, Hanover
Bielefeld Clinical Centre, Bielefeld
University Hospital Gießen, Giessen
University Hospital Göttingen, Göttingen
Helios Hospital, Wuppertal
University Hospital Cologne, Cologne
Hospital Lüdenscheid, Lüdenscheid
Ludwigshafen Hospital, Ludwigshafen
Westpfalz-Clinic GmbH Kaiserslautern, Kaiserslautern
University Hospital Mannheim, Mannheim
University Hospital Tübingen, Tübingen
Municipal Clinical Center Karlsruhe, Karlsruhe
St. Vincentius Hospital, Karlsruhe
Schwarzwald-Baar Hospital Villingen Schwenningen, Villingen-Schwenningen
Heart Center Freiburg University Bad Krozingen, Bad Krozingen
Peter Osypka Heart Center, Munich
Heart Center Bad Neustadt-Saale, Bad Neustadt an der Saale
Dept. of Medicine-Cardiology University Clinic Bonn, Bonn
Heart Center Leipzig, Leipzig
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
Georg Nickenig
OTHER